SCHEMBL23218917

SCHEMBL23218917

CCOC(=O)Cc1ccccc1OCc1coc2c(NCC3CC3)cc(Cl)cc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.38
NPC1 O15118 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 3/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
TBXAS1 P24557 1/20 0.35
GPBAR1 Q8TDU6 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
GRIN2B Q13224 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CFD P00746 1/20 0.33
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852993 1.00 PTGER4 (0.38) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL29591282 0.97 PTGER4 (0.35) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL29852426 0.97 PTGER4 (0.35) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL23219001 0.97 PTGER4 (0.35) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL29852609 0.92 LRRK2 (0.34) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL23218396 0.92 LRRK2 (0.34) PTGER4NPC1MEN1KMT2AMAPT
SCHEMBL23218123 0.90 MAPT (0.38) NPC1MEN1KMT2AMAPTTP53
SCHEMBL29853049 0.90 MAPT (0.38) NPC1MEN1KMT2AMAPTTP53
SCHEMBL29591621 0.90 MAPT (0.38) NPC1MEN1KMT2AMAPTTP53
SCHEMBL23219081 0.89 HPGD (0.42) MEN1KMT2AMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGER4 3027/4885NPC1 324/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGER4 2238/4885NPC1 311/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.